BROWSE·page 87 of 327

Browse EX-10 agreements

3,923 matching material contract exhibits.


July 8, 2026

Dear Steve:

This revised letter agreement (this “Agreement”) sets forth the terms and conditions of your (referred to as “you” or “your” or “executive”) employment with Longeveron Inc. (the “Company”), which shall be effective as of February 11, 2026 (the “Effective Date”). This Agreement will govern your employment with the Company following the Effective Date on the following terms and conditions:

| |

EX-10.1·8-K·CIK 1721484·ACC 0001213900-26-078019·Filed Jul 14, 2026, 17:19 ET

EX-10.1

FIRST BUSEY CORP /NV/

FIRST BUSEY CORPORATION 11440 TOMAHAWK CREEK PARKWAY LEAWOOD, KS 66211 -1- July 13, 2026 Van A. Dukeman At the address on file with the Corporation Dear Van: Reference is made to your Employment Agreement, dated as of December 26, 2001, by and between you and First Busey Corporation (the “Corporation”), as amended from time to time (your “Original Agreement”), and as further amended pursuant to the Letter Agreement between you and the Corporation, dated as of August 26, 2024 (the “Prior Letter Agreement” and, together with your Original Agreement, your “Employment Agreement”). In connection with the Corporation’s ongoing succession planning, you and the Corporation have agreed to extend your expected term serving as Chief Executive Officer of the Corporation and Chief Executive Officer of Busey Bank (the “Bank”) through July 1, 2029 (the “Expected Term”). You will also continue to serve as President of the Corporation, and as Chairman of the Board of Directors of the Corporation and of the Board of Directors of the Bank. This letter agreement confirms to you, and you agree, that your

EX-10.1·8-K·CIK 314489·ACC 0000314489-26-000046·Filed Jul 14, 2026, 17:06 ET

EXHIBIT 10.1

Bridgeline Digital, Inc.

BRIDGELINE DIGITAL, INC.

COMMON STOCK 

SALES AGREEMENT

July 14, 2026

WestPark Capital, Inc.

1800 Century Park East, Suite 220

Los Angeles, CA 90067

Ladies and Gentlemen:

Bridgeline Digital, Inc. (the “Company”), confirms its agreement (this “Agreement”) with WestPark Capital, Inc. (“WestPark), as follows:

1.      Issuance and Sale of Placement Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through WestPark, shares (the “Placement Shares”)* *of the Company’s common stock, $0.001 par value per share (the “Common Stock”); *provided however, *that in no event shall the Company issue or sell through WestPark such number of Placement Shares that (a) exceeds the number of shares or dollar amount of Common Stock registered on the effective Registration Statement (as defined below) pursuant to which the offering is being made, (b) exceeds the number of shares or dollar amount registered on the Prospectus Supplem

EX-10.1·8-K·CIK 1378590·ACC 0001437749-26-023553·Filed Jul 14, 2026, 17:01 ET

EXHIBIT 10.2

Anika Therapeutics, Inc.

CONSENT AND FOURTH AMENDMENT TO CREDIT AGREEMENT

THIS CONSENT AND FOURTH AMENDMENT TO CREDIT AGREEMENT (this“Agreement”), dated as of October 30, 2024 (the “SOFR Amendment Effective Date”), is entered into by BANK OF AMERICA, N.A., as administrative agent (the “Administrative Agent”).

RECITALS

WHEREAS, ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party thereto, the lenders from time to time party thereto (the “Lenders”), and Bank of America, N.A., as Administrative Agent, have entered into that certain Credit Agreement, dated as of October 24, 2017 (as amended by that certain First Amendment to Credit Agreement, dated as of August 13, 2019, as further amended by that certain Second Amendment to Credit Agreement and First Amendment to Security Agreement, dated as of May 14, 2020, that certain Third Amendment to Credit Agreement, dated as of November 12, 2021 (as amended, modified, extended, restated, replaced, or supplemented fromtime to time, the “Credit Agreement”);

EX-10.2·8-K·CIK 898437·ACC 0001171843-26-004635·Filed Jul 14, 2026, 17:00 ET

EXHIBIT 10.1

Anika Therapeutics, Inc.

Execution Version

FIFTH AMENDMENT TO CREDIT AGREEMENT

This FIFTH AMENDMENT TO CREDIT AGREEMENT, dated as of July 10, 2026 (this “Fifth Amendment”), is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto (if any), each lender party hereto, and the Administrative Agent (as defined below), and modifies that certain Credit Agreement, dated as of October 24, 2017 (as amended by that certain First Amendment to Credit Agreement, dated as of August 13, 2019, as further amended by that certain Second Amendment to Credit Agreement and First Amendment to Security Agreement, dated as of May 14, 2020, as further amended by that certain Third Amendment to Credit Agreement, dated as of November 12, 2021, as further amended by that certain Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”), dated as of October 30, 2024, and as may be further amended, restated, amended and restated, extended, supplemented or otherwise modified in writing from time to time and in effect immediately p

EX-10.1·8-K·CIK 898437·ACC 0001171843-26-004635·Filed Jul 14, 2026, 17:00 ET

EX-10.3

Research Alliance Corp IV

**PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT **

THIS PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), dated as of July 10, 2026, is entered into by and between Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”), and Research Alliance Holdings IV LLC, a Cayman Islands limited liability company (the “Purchaser”).

WHEREAS, the Company intends to consummate an initial public offering (the “Public Offering”) of the Company’s Class A ordinary shares, par value $0.0001 per share (each, a “Share”), as set forth in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”), File Number 333-296609 under the Securities Act of 1933, as amended (the “Securities Act”).

WHEREAS, the Purchaser has agreed to purchase an aggregate of 275,000 Shares (the “Private Placement Shares”).

EX-10.3·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.4

Research Alliance Corp IV

***FORM OF INDEMNITY AGREEMENT ***

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of July 10, 2026, by and between Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”), and __________ (“Indemnitee”).

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

EX-10.4·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.6

Research Alliance Corp IV

**Exhibit 10.6 **

Research Alliance Corporation IV

600 Fifth Avenue, 23rd Floor

New York, New York 10020

Re: **Initial Public Offering **

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”) and Leerink Partners LLC, as the sole underwriter named therein (the “Underwriter”), relating to an underwritten initial public offering (the “Public Offering”) of up to 7,500,000 of the Company’s Class A ordinary shares, par value $0.0001 per share ( “Ordinary Shares”). The Ordinary Shares will be sold in the Public Offering pursuant to a registration statement on Form S-1 and a prospectus (the “Prospectus”) filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”). Certain capitalized terms used her

EX-10.6·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.5

Research Alliance Corp IV

RESEARCH ALLIANCE CORPORATION IV

600 Fifth Avenue, 23rd Floor

New York, New York 10020

July 10, 2026

Research Alliance Holdings IV LLC

c/o RA Capital

200 Berkeley Street, 18th Floor

Boston, MA 02116

Ladies and Gentlemen:

(a) This letter agreement (this “Agreement”) will confirm our agreement that, to the fullest extent permitted by applicable law, the Company agrees to defend, indemnify, hold harmless and exonerate (including the advancement of expenses to the fullest extent permitted by applicable law) the Sponsor, its directors, officers, employees, principals, managers, partners, members, shareholders, equityholders, control persons, affiliates, agents, advisors, consultants and representatives, including for the avoidance of doubt RA Capital Management, L.P. (“RA Capital Management”), (the “Indemnitees”), from any claims, losses, liabilities, obligations, causes of action, proceedings (whether pending or threatened), investigations, damages, awards, settlements, judgments, decrees, fees, costs, penalties, amounts paid in settlement or expenses (including interest, assess

EX-10.5·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.2

Research Alliance Corp IV

REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT

THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of July 10, 2026, is made and entered into by and among Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”), Research Alliance Holdings IV LLC, a Cayman Islands limited liability company (the “Sponsor”), and the undersigned parties listed under Holder on the signature page hereto (each such party, including the Sponsor and any person or entity who hereafter becomes a party to this Agreement pursuant to Section*** 6.2* of this Agreement, a “Holder” and collectively, the “Holders”).

RECITALS

WHEREAS, the Sponsor currently owns 1,263,529 shares of the Company’s Class B ordinary shares, par value $0.0001 per share (the “Class B Ordinary Shares”), and the other Holders currently own an aggregate of 60,000 Class B Ordinary Shares, which were received from the Sponsor;

EX-10.2·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.1

Research Alliance Corp IV

INVESTMENT MANAGEMENT TRUST AGREEMENT

This Investment Management Trust Agreement (this “Agreement”) is made effective as of July 10, 2026 by and between Research Alliance Corporation IV, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).

WHEREAS, the Company’s registration statement on Form S-1, File No. 333-296609 (the “Registration Statement”) and prospectus (the “Prospectus”) for the initial public offering of the Company’s Class A ordinary shares, par value $0.0001 per share (“Ordinary Shares”) (such initial public offering hereinafter referred to as the “Offering”), has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission; and

WHEREAS, the Company has entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as sole underwriter named therein; and

EX-10.1·8-K·CIK 2137777·ACC 0001193125-26-303344·Filed Jul 14, 2026, 16:58 ET

EX-10.1

Accel Entertainment, Inc.

TRANSITION AGREEMENT

This TRANSITION AGREEMENT(“Agreement”), is entered into as of July 14, 2026 (the “Effective Date”), by Accel Entertainment, Inc., a Delaware corporation (the “Company”), and Derek Harmer (“Harmer”), and amends that certain Executive Employment Agreement by and between the Company and Harmer dated July 16, 2020, and amended as of July 15, 2023 (the “Employment Agreement”).

WHEREAS, the Employment Agreement and Harmer’s employment with the Company shall terminate as set forth herein;

EX-10.1·8-K·CIK 1698991·ACC 0001698991-26-000053·Filed Jul 14, 2026, 16:50 ET